Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 58–59
HOS-109018 · Präparat HOS-093083
58 Ergot alkaloids Dihydroergotamine, Serum concentrations may be Concomitant administration of ergonovine, ergotamine, increased due to CYP3A Kaletra and ergot alkaloids are methylergonovine inhibition by lopinavir/ritonavir. contraindicated as it may lead to acute ergot toxicity, including vasospasm and ischaemia (see section 4.3). GI motility agent Cisapride Serum concentrations may be Concomitant administration of increased due to CYP3A Kaletra and cisapride is inhibition by lopinavir/ritonavir. contraindicated as it may increase the risk of serious arrhythmias from this agent (see section 4.3). HCV direct acting antivirals Elbasvir/grazoprevir Concomitant administration of (50/200 mg QD) Elbasvir: elbasvir/grazoprevir with Kaletra is AUC: ↑ 2.71-fold contraindicated (see section 4.3). Cmax: ↑ 1.87-fold C24: ↑ 3.58-fold
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) methylergonovine (HOS-086155) cisapride (HOS-085610) ergot alkaloids (HOS-108807) lead (HOS-085592) grazoprevir (HOS-108815) ergotamine (HOS-086154) ergonovine (HOS-086153) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 4e77c7177dcb09470b14c97ed8c2db4a61223a16317eda0c5c9a5dac826ac90b · Zeichen 48980–50461 im Abschnitt